1 – 10 of 24
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders
(
- Contribution to journal › Article
- 2022
-
Mark
Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy
(
- Contribution to journal › Article
- 2021
-
Mark
Differences in antipsychotic treatment between depressive patients with and without a suicide attempt
(
- Contribution to journal › Article
- 2020
-
Mark
A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration
(
- Contribution to journal › Article
-
Mark
Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care
(
- Contribution to journal › Article
- 2019
-
Mark
A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting
(
- Contribution to journal › Article
- 2017
-
Mark
Impact of generic substitution on levetiracetam serum concentration : A prospective study in an outpatient setting
(
- Contribution to journal › Article
-
Mark
Impact of generic substitution on levetiracetam serum concentration - a prospective study in an outpatient setting
2017) 2017 American Epilepsy Society (AES) Annual Meeting(
- Contribution to conference › Abstract
- 2016
-
Mark
Ongoing Pharmacological Management of Chronic Pain in Pregnancy
(
- Contribution to journal › Article
-
Mark
Antipsychotics - Postmortem fatal and non-fatal reference concentrations
(
- Contribution to journal › Article